Cambrex Corp (CBM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cambrex Corp (CBM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5330
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cambrex Corp (Cambrex) is a life science company that focuses on the development and commercialization of small molecule therapeutics. The company’s major products include active pharmaceutical ingredients (APIs), advanced intermediates and drug delivery products for branded and generic pharmaceuticals. It serves various generic drug companies and companies that discovers and commercializes small molecule human therapeutics using organic chemistry. Cambrex has its R&D and manufacturing facilities in the US and Europe. The company markets its products directly and also through a network of independent agents across Europe, North America and Asia, among others. Cambrex is headquartered in East Rutherford, New Jersey, the US.

Cambrex Corp (CBM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cambrex Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cambrex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Cambrex Corp, Pharmaceuticals & Healthcare, Deal Details 9
Acquisition 9
Cambrex to Acquire Halo Pharma from SK Capital Partners for USD425 Million 9
Cambrex Acquires PharmaCore for USD24.275 Million 11
Cambrex Acquires 100% Stake in Zenara Pharma 12
Cambrex Corp – Key Competitors 13
Cambrex Corp – Key Employees 14
Cambrex Corp – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Strategy And Business Planning 16
Sep 26, 2017: Cambrex opens API manufacturing facility and invests in supporting waste water treatment plant at its Karlskoga, Sweden site 16
Aug 08, 2017: Cambrex invests $24 million in new highly potent API manufacturing capacity at its Charles City, Iowa facility 17
Financial Announcements 18
Aug 02, 2018: Cambrex reports second quarter 2018 financial results 18
May 03, 2018: Cambrex Reports First Quarter 2018 Financial Results 20
Feb 08, 2018: Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results 22
Nov 07, 2017: Cambrex Reports Third Quarter 2017 Financial Results 24
May 04, 2017: Cambrex Reports First Quarter 2017 Financial Results 26
Feb 03, 2017: Cambrex Reports Fourth Quarter and Full Year 2016 Financial Results 28
Corporate Communications 30
Nov 03, 2017: Gregory B. Brown M.D. Appointed to the Board of Directors of Cambrex Corporation 30
Jan 04, 2017: Cambrex Appoints Tom Vadaketh as Executive Vice President and Chief Financial Officer 31
Other Significant Developments 32
Jun 12, 2018: Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site 32
May 31, 2018: Cambrex Invests $5 Million in New Laboratory Expansion at its Karlskoga, Sweden Facility 33
Apr 23, 2018: Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility 34
Apr 17, 2018: Cambrex Invests in New Continuous Flow Technology at its High Point, NC Facility 35
Jan 30, 2018: Cambrex Expands Process Research and Development Capabilities Across North America 36
Oct 12, 2017: Cambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan Site 37
Aug 30, 2017: Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility 38
Aug 08, 2017: Cambrex invests $24 million in new highly potent API manufacturing capacity at its Charles City, Iowa facility 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Cambrex Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cambrex Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cambrex Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Cambrex to Acquire Halo Pharma from SK Capital Partners for USD425 Million 9
Cambrex Acquires PharmaCore for USD24.275 Million 11
Cambrex Acquires 100% Stake in Zenara Pharma 12
Cambrex Corp, Key Competitors 13
Cambrex Corp, Key Employees 14
Cambrex Corp, Other Locations 15
Cambrex Corp, Subsidiaries 15

List of Figures
Cambrex Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cambrex Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cambrex Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[Cambrex Corp (CBM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Northern Ireland Electricity Networks Ltd:企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Easywell Biomedical Inc (1799):医療機器:M&Aディール及び事業提携情報
    Summary Easywell Biomedical Inc (Easywell), formerly Actherm Inc is a supplier of medical devices, pharmaceuticals and regenerative medicines. The company’s medical devices comprise pain and systems, non-contact, forehead infrared thermometer, infrared ear thermometer and digital clinical thermomete …
  • Impel NeuroPharma Inc:医療機器:M&Aディール及び事業提携情報
    Summary Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delive …
  • Ora Gold Ltd (THX):企業の財務・戦略的SWOT分析
    Summary Ora Gold Ltd (Ora Gold) is a mining and mineral exploration company. The company acquires, explores and develops lead, zinc, silver, nickel, graphite, copper, gold and uranium prospects in Western Australia and the Northern Territory. Its projects include Red Bore Copper-Gold Project, Garden …
  • Oakdale Electric Cooperative:企業の戦略的SWOT分析
    Oakdale Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Vermont Electric Cooperative Inc:企業の戦略的SWOT分析
    Vermont Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Galilee Energy Ltd (GLL):石油・ガス:M&Aディール及び事業提携情報
    Summary Galilee Energy Ltd (Galilee) is a mining and minerals exploration and development company that offers exploration and development services. The company acquires, explores, produces, and develops coal seam gas in the Galilee Basin near Longreach in Queensland. It offers projects such as ATP79 …
  • EpiVax Inc-製薬・医療分野:企業M&A・提携分析
    Summary EpiVax Inc (EpiVax) is an immunology company which develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear se …
  • Entellus Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Entellus Medical Inc (Entellus Medical), a subsidiary of Stryker Corp, is a medical device company that offers invasive products for the treatment of chronic sinusitis. The company’s products include multi sinus dilation system, surgical instruments, sinonasal suction and irrigation system, …
  • St. George Bank Limited:企業の戦略・SWOT・財務情報
    St. George Bank Limited - Strategy, SWOT and Corporate Finance Report Summary St. George Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Beijer Ref Ab:企業のM&A・事業提携・投資動向
    Beijer Ref Ab - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Beijer Ref Ab Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Warrnambool Cheese and Butter Factory Company Holdings Limited:企業の戦略・SWOT・財務情報
    Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cov …
  • KDDI Corporation:企業のM&A・事業提携・投資動向
    KDDI Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's KDDI Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Merck & Co., Inc.:企業のM&A・事業提携・投資動向
    Merck & Co., Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merck & Co., Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Syngenta AG:企業の戦略・SWOT・財務分析
    Syngenta AG - Strategy, SWOT and Corporate Finance Report Summary Syngenta AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Metrion Biosciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Metrion Biosciences Ltd (Metrion Biosciences) is a contract research organization that offers ion channel drug discovery services. The organization offers cardiac safety screening services, neuroscience-related assays and platforms and translational assays. Its ion channel screening services …
  • Enyo Pharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Enyo Pharma SA (Enyo Pharma) is a biopharmaceutical company that develops molecules modulating host functions for the treatment of acute and chronic viral infections. The company provides technology which develops tools combining biological experimentation and computational development to id …
  • Petroleos de Venezuela SA-エネルギー分野:企業M&A・提携分析
    Summary Petroleos de Venezuela SA (PDVSA) is a state-owned oil and gas company. It plans, coordinates, supervises, and controls the activities in the entire oil and gas value chain. The company explores for and develops oil and other hydrocarbons; refines, trades, and supplies that in domestic and o …
  • Everest Industries Ltd:企業の戦略・SWOT・財務情報
    Everest Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Everest Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Energy Development Corporation (EDC):企業の財務・戦略的SWOT分析
    Energy Development Corporation (EDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆